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Abstract. Recent evidence indicates mass drug administration with azithromycin may reduce child mortality. This
studyuses verbal autopsy (VA) to investigate thecausesof individual deathsduring theMacrolidesOrauxpourRéduire les
Décès avec un Oeil sur la Résistance (MORDOR) trial in Malawi. Cluster randomization was performed as part of
MORDOR.Biannual household visitswere conducted to distribute azithromycin or placebo to children aged 1–59months
and update the census to identify deaths for VA. MORDORwas not powered to investigate mortality effects at individual
sites, but the available evidence is presented here for hypothesis generation regarding the mechanism through which
azithromycinmay reducechildmortality. AutomatedVAanalysiswasperformed to infer the likely causeof deathusing two
major analysis programs, InterVA and SmartVA. A total of 334 communities were randomized to azithromycin or placebo,
with more than 130,000 person-years of follow-up. During the study, there were 1,184 deaths, of which 1,131 were
followed upwith VA.Mortality was 9% lower in azithromycin-treated communities than in placebo communities (rate ratio
0.91 [95% CI: 0.79–1.05]; P = 0.20). The intention-to-treat analysis by cause using InterVA suggested fewer HIV/AIDS
deaths in azithromycin-treated communities (rate ratio 0.70 [95% CI: 0.50–0.97]; P = 0.03) and fewer pneumonia deaths
(rate ratio 0.82 [95% CI: 0.60–1.12]; P = 0.22). The use of the SmartVA algorithm suggested fewer diarrhea deaths (rate
ratio 0.71 [95% CI: 0.51–1.00]; P = 0.05) and fewer pneumonia deaths (rate ratio 0.58 [95% CI: 0.33–1.00]; P = 0.05).
Although this study is not able to provide strong evidence, the data suggest that themortality reduction duringMORDOR
in Malawi may have been due to effects on pneumonia and diarrhea or HIV/AIDS mortality.
INTRODUCTION
Mass drug administration (MDA) with azithromycin is widely
used by trachoma control programs as part of efforts to
eliminate trachoma, the leading infectious cause of blindness
globally.1 During interventions principally aimed at eliminating
trachoma, evidence emerged of reductions in a number of
infectious diseases following azithromycin MDA, including
diarrhea,2 pneumonia,3 and malaria.4–6 A study from Ethiopia
reported a large reduction in child mortality following azi-
thromycinMDA.7 Expert opinion suggested that a reduction in
mortality was likely but to a lesser extent than estimated in this
single available trial.8 MORDOR was a large multicenter trial
that recently tested the hypothesis that biannual azithromycin
MDA to children aged 1–59 months would reduce childhood
mortality, reporting a 14% overall reduction in mortality in
those assigned to azithromycin versus placebo.9 There is
limited literature related to the mechanism through which
azithromycin MDA may reduce child mortality. As a broad-
spectrum antibiotic with weak antimalarial activity that has
shown reductions in morbidity from pneumonia, diarrhea, and
malaria, an effect on mortality from any of these major causes
is feasible. In addition, azithromycinmay reduce opportunistic
infections in HIV-positive individuals, including Mycobacte-
rium avium complex, and investigation is underway regarding
its effect on HIV-associated chronic lung disease.10,11
Ideally, the underlying cause of death would be determined
from medical certificates of cause of death completed by
physicians with access to adequate investigative resources.
However, at the MORDOR-Malawi study site, as in low-
income settings in much of sub-Saharan Africa, there was
limited access to physicianswhowould be able to complete
death certificates. In such contexts, verbal autopsy (VA)—a
structured interview with relatives of the deceased to as-
certain cause of death—is increasingly used to infer likely
causes of death. Development of standard electronic
questionnaires on mobile devices and automated analysis
programs have improved the feasibility of VA and compa-
rability of results, compared with the previous require-
ment for physician review of the interviews.12 Prediction of
cause-specific mortality fractions in a population using VA
may be approximately 60–80%accurate, although lower for
individual-level diagnosis.13,14 In settings where more ac-
curate determination of cause of death is not possible, VA
may be used to produce probable cause of death data with
the caveat of it being an imperfect tool.15 The two most
commonly used VA analysis programs are InterVA16 and
SmartVA.17 InterVA uses a probabilistic model based on
the relationship between indicators and causes, as cap-
tured through expert panel discussions.18 SmartVA, or the
Tariff method, is based on the symptom–cause information
from the Population Health Metrics Research Consortium
(PHMRC) study that included more than 12,000 VA interviews
performed on deaths with a gold standard diagnosis derived
from stringent diagnostic criteria.19,20
The MORDOR trial was designed to assess overall mortal-
ity over three country sites and cause of death has not pre-
viously been compared between treatment arms for this
study. Although azithromycinMDA has been shown to reduce
morbidity due to the leading causes of child mortality outlined
previously, there is no evidence to date for a cause-specific
mortality effect of azithromycinMDA. As interest andevidence
increases regarding the mortality benefit of azithromycin, an
understanding of the mechanism for that benefit remains un-
clear. This study used VA methods to assess causes of death
in children enrolled in the MORDOR trial in Malawi.
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METHODS
Trial design and participants. The methods for the main
MORDOR trial in Niger, Tanzania, and Malawi are described
elsewhere.9 Briefly, MORDOR assessed the effects of bi-
annual single-dose azithromycin MDA compared with pla-
cebo on mortality in children aged 1–59 months. The trial was
cluster randomized and in Malawi used the catchment area of
a Health Surveillance Assistant (HSA) as a cluster. The study
area covered the whole of Mangochi District and took place
between March 2015 and June 2017, including a total of four
treatment rounds and five census visits. Children were in-
cluded if theywere aged between 1 and 59months at the start
of any inter-census period. Biannual house-to-house census
was conducted to identify all deaths as well as new births and
migrations into or out of the study area.
TheMORDOR trial included 304 clusters randomly selected
from a pool of 334 clusters meeting the inclusion criteria iden-
tified from a pre-baseline census. The remaining 30 clusters,
randomly located throughout the study area, were used for
assessment of morbidity outcomes. This study, assessing
cause-specific mortality, included deaths that occurred in all
334 communities, in the interests of presenting all available
data.
Interventions. Azithromycin was administered at a dose of
20 mg/kg to all children available in study communities. Ad-
ditionalmop-up visits were conducted to increase the number
of children treated. Children able to stand received an ap-
proximate dose based on their height, and small childrenwere
weighed. Placebo bottles and suspension were identical in
appearance to azithromycin. Distribution of drug was per-
formed by HSAs and MORDOR fieldworkers conducting
house-to-house visits. Guardians were asked to inform the
HSA of any adverse events that occurred within 7 days of
receiving the study drug and HSAs were trained to inform the
study team.
Outcomes. The primary prespecified outcome was cause
of death, inferred using VA methods, for deaths in children
aged 1–59 months at the prior census. A secondary pre-
specified outcome was seasonality of deaths. Both the
InterVA and SmartVA automated analysis algorithms are en-
dorsed by the WHO and performance overall is not greatly
dissimilar between the methods.14 The sensitivity and speci-
ficity for diagnosis of specific causes does, however, vary
considerably between the two algorithms, including for the
four major causes of child mortality in this setting: malaria,
pneumonia, diarrhea, and HIV/AIDS, as identified by Murray
et al.14 and shown in Supplemental Table 7 for reference and
discussion in the following paragraphs. This study used the
WHO 2014 VA questionnaire with analysis using both the
InterVA and SmartVA algorithms to provide a comprehensive
and transparent assessment of the available data.
Data collection. Census data collection used custom-
made software on Google Android devices. Deaths were
identified from census updates andwere followed upwith VA
interviews. Three nurses were trained to conduct VA inter-
views and aimed to complete these within 12 months of the
death as recall is expected to diminish after this time.21 The
WHO 2014 VA questionnaire was installed on Android de-
vices using ODK Collect software. Data were uploaded to a
secure server at the London School of Hygiene and Tropical
Medicine.
Sample size. The MORDOR trial was designed to assess
the effect of azithromycin on overall mortality in children
aged 1–59 months with 84% power to detect a 15% effect
over 2 years. The study was not designed to assess cause-
specific mortality, which would require a significantly larger
trial size.
Randomization and blinding. The study drug was labeled
with 16 letters by themanufacturer (Pfizer Inc., NewYork, NY),
with half corresponding to azithromycin and half to placebo.
Communities, being the villages under a single HSA, were
randomly assigned to a drug letter by the study statistician in
San Francisco using the statistical package R (R Foundation
for Statistical Computing, Vienna, Austria). All staff and par-
ticipants in Malawi were blind to the treatment code until all
data collection and cleaning was complete.
Statistical methods. The automated analysis programs
used to produce inferred cause of death data, InterVA version
4 (InterVA version 4, University of Umeå, Umeå, Sweden) and
SmartVA-Analyze (SmartVA-Analyze, Institute for Health
Metrics and Evaluation, University of Washington, Seattle,
WA), have thresholds for identifying the cause of death and if
these are not met, the outcome is listed as “indeterminate” or
“undetermined.”16,17 The SmartVA analysis software redis-
tributes unknown causes of death according to the certainty
of the algorithm in predicting different causes of death and
Global Burden of Disease patterns for the country.22 As the
SmartVA redistribution reflects the inherent ability of the
program to predict each cause, redistribution may provide
more accurate estimation of cause-specific mortality rates
than the SmartVA output without redistribution; where pos-
sible, output with and without redistribution is presented.
Output with redistribution is presented without CIs as this is
produced by the SmartVA software at the population level
rather than subsequently calculated from individual-level
cause of death data.
Statistical analysis was performed using Stata version 15.1.
Primary analyses were by intention-to-treat (ITT); to in-
vestigate if any cause-specific effects onmortality were due to
individual or community-level effects of azithromycin, sec-
ondary per protocol (PP) analyses were performed that in-
cluded only individualswho received treatment as indicated at
the previous visit. Cause-specific mortality rates were calcu-
lated, and Poisson regression models produced, for the four
main causes of mortality in the study area (pneumonia, di-
arrhea, HIV/AIDS, and malaria), with treatment allocation as
the main predictor variable and random effects for clustering
at the level of the MORDOR randomization unit. Point esti-
mates with CIs from the models are presented as the best
available estimates of the effect of azithromycin on cause-
specific mortality in this population.
As an independent analysis to the VA algorithm outputs, the
proportion of individuals with open response terms and pos-
itive responses to VA questions related to the major causes of
child mortality were also assessed, specifically the open re-
sponse terms “malaria,” “pneumonia,” and “diarrhea” and VA
items “maternal test positive for HIV,” “frequent loose/liquid
stool continuing until death,” “very severe cough,” and “se-
vere fever”. A two-tailed test of proportions was used and
P values are presented. Maternal HIV status was selected
to estimate HIV exposure as very few children had a known
HIV status, whereas mothers were more likely to have been
tested for HIV during antenatal visits.
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Study visits took place around the beginning and end of the
dry season in Malawi, which occurs approximately between
May and October. The baseline, 12-month, and 24-month
visits took place between April and June 2015, 2016, and
2017, respectively; and the 6-month and 18-month visits
between September and December 2015 and 2016. For the
analysis of seasonality, dry season deaths were defined as
those occurring between the baseline and 6-month visits and
between the 12-month and 18-month visits, and wet season
deaths as those occurring between the 6-month and 12-
month visits and between the 18-month and 24-month visits.
Univariate Poisson regression models were produced to as-
sess the effects of treatment allocation during both the wet
and dry seasons on each of the main causes of child mortality.
RESULTS
In the 334 randomization units in the MORDOR trial in
Malawi, there were 133,772 person-years of follow-up for
children aged 1–59 months at the prior census. Person-years
of follow-up and mortality rates were similar between males
and females at each round, shown in Table 1. Over the course
of the study, there were 1,184 deaths and VAs were com-
pleted for 1,131 of these. Median delay from death to VA was
5 months (range 1–26 months), with 87% of VAs completed
within 12 months of death.
Mortality was 9% lower in azithromycin-treated communi-
ties compared with those allocated to placebo (rate ratio 0.91
[95% CI: 0.79–1.05]; P = 0.20). The top 10 causes of death
using the InterVA algorithm are shown in Table 2, and using
the SmartVA algorithm in Table 3. Malaria was the leading
cause of death overall, followed by HIV/AIDS, using both al-
gorithms without redistribution of undetermined cases, and
diarrhea, pneumonia, and either acute abdomen (InterVA) or
other digestive diseases (SmartVA) made up the top five
causes. The top 10 causes including redistribution of unde-
termined cases for SmartVA are also shown in Table 3.
Pneumonia, malaria, diarrhea, and HIV/AIDS accounted for
83% and 78% of the inferred causes of death using InterVA
and SmartVA with redistribution, respectively.
The ITT analyses of cause-specific mortality rates are
shown using InterVA in Table 4 and SmartVA in Table 5. The
analysis using InterVA showed 30% lower HIV/AIDS mortality
in azithromycin-treated communities (rate ratio 0.70 [95% CI:
0.50–0.97]; P = 0.03), but this trend was not evident using
SmartVA (rate ratio 0.99 [95%CI: 0.71–1.38];P= 0.95) without
redistribution and rate ratio 0.92 with redistribution. The effect
estimate for pneumonia mortality was lower in azithromycin
communities using both InterVA (rate ratio 0.82 [95% CI:
0.60–1.12]; P = 0.22) and SmartVA (rate ratio 0.58 [95% CI:
0.33–1.00]; P = 0.05) without redistribution and rate ratio 0.87
with redistribution.
Inferred malaria mortality was similar in azithromycin com-
munities compared with placebo using InterVA (rate ratio 0.95
[95% CI: 0.78–1.16]; P = 0.64) and SmartVA (rate ratio 0.93
[95% CI: 0.76–1.14]; P = 0.49) without redistribution and rate
ratio 0.94 with redistribution. The effect estimate for diarrhea
mortality was similar in azithromycin communities compared
with placebo when analyzed using InterVA (rate ratio 0.95
[95%CI: 0.61–1.49]; P = 0.84) but was lower in azithromycin
communities when analyzed using SmartVA (rate ratio 0.71
[95%CI: 0.51–1.00];P = 0.05) without redistribution and rate
ratio 0.72with redistribution. The analyses of cause-specific
mortality rates PP are shown in Supplemental Table 1 using
InterVA, and Supplemental Table 2 using SmartVA. Cause-
specific rate ratios PP were similar to those by ITT; within
10% for all causes.
Cause-specific mortality rates for the leading causes of
child mortality are shown by follow-up period in Figure 1.
Pneumonia mortality rates were lower in azithromycin than
placebo communities at three of the four follow-up visitswhen
analyzed using InterVA and at all follow-up visits using
SmartVA. HIV/AIDS mortality appears generally lower in
azithromycin communities using InterVA and diarrhea mor-
tality generally lower using SmartVA; no such patterns are
evident for malaria mortality.
The comparison of VA response terms is shown in Table 6.
In the ITT analysis, the open response term “pneumonia”was
more frequently reported in VAs conducted in placebo com-
munities than azithromycin: 8.2% versus 5.1%, respectively;
P = 0.03. The open response term “diarrhea” was also more
frequently reported in placebo than azithromycin communi-
ties: 21.9% versus 16.9%, respectively; P = 0.03. The VA item
“frequent loose/liquid stool continuing until death” was more
frequently endorsed in placebo than azithromycin communi-
ties: 37.2% versus 30.1%, respectively; P = 0.01. The open
response term “malaria” was similar between placebo and
azithromycin arms: 45.7% versus 49.1%, respectively; P =
0.26. “Maternal test positive for HIV,” “very severe cough,”
and “severe fever” were all similar between treatment arms.
The PP analyses showed similar trends to the ITT results.
Assessment of seasonality by ITT using InterVA and
SmartVA did not identify clear trends for differences in cause-
specificmortality between treatment arms; these analyses are
included as Supplemental Data. Analysis using the InterVA
algorithm suggested an effect of azithromycin on pneumonia
mortality during the wet season but not the dry (wet season
rate ratio 0.64 [95% CI: 0.41–1.00]; P = 0.05) and dry season
rate ratio 1.02 [95% CI: 0.65–1.61]; P = 0.93) (Supplemental
Table 3). Analysis using SmartVA, however, predicted ap-
proximately two-thirds fewer pneumonia deaths overall and
the same seasonal trend was not evident (wet season rate
TABLE 1





Number of deaths (followed
up with verbal autopsy)
Rate per 1,000 person-
years (95% CI)
0–6 months follow-up
Female 13,371 124 (118) 9.27 (7.78–11.06)
Male 13,398 135 (126) 10.08 (8.51–11.93)
Total 26,768 259 (244) 9.68 (8.57–10.93)
6–12 months follow-up
Female 19,095 174 (168) 9.11 (7.85–10.57)
Male 19,031 181 (175) 9.51 (8.22–11.00)
Total 38,126 355 (343) 9.31 (8.39–10.33)
12–18 months follow-up
Female 15,547 124 (123) 7.98 (6.69–9.51)
Male 15,356 117 (108) 7.62 (6.36–9.13)
Total 30,903 241 (231) 7.80 (6.87–8.85)
18–24 months follow-up
Female 19,100 162 (154) 8.48 (7.27–9.89)
Male 18,875 167 (159) 8.85 (7.60–10.30)
Total 37,975 329 (313) 8.66 (7.78–9.65)
Grand
total
133,772 1,184 (1,131) 8.85 (8.36–9.37)
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ratio 0.71 [95% CI: 0.32–1.61]; P = 0.42 and dry season rate
ratio 0.48 [95% CI: 0.23–1.02]; P = 0.06) (Supplemental
Table 4). Analysis using InterVA suggested lower HIV/AIDS
mortality in azithromycin communities during both thewet and
dry seasons, whereas the SmartVA analysis suggested lower
diarrhea mortality in azithromycin communities during both
seasons. The PP analyses using InterVA and SmartVA show
generally similar results to the ITT analysis and are included for
completeness as Supplemental Tables 5 and 6, respectively.
DISCUSSION
This study investigated the effect of azithromycin MDA on
each of the major causes of child mortality in Mangochi Dis-
trict, Malawi, during the MORDOR trial. Verbal autopsy was
used to infer the likely causes of death. The relative effects of
azithromycin on cause-specific mortality during the wet and
dry seasons was also assessed. The effect estimates pro-
duced in this study are mostly compatible with there being
zero effect but are the only estimates available to date for the
effect of azithromycin MDA on cause-specific child mortality.
The effect estimates using the InterVA analysis algo-
rithm suggest lower pneumonia and HIV/AIDS mortality in
azithromycin-treated than in placebo communities. Using
SmartVA, the results suggest lower pneumonia and diarrhea
mortality in azithromycin communities. The analysis of VA
responses indicates that the terms “pneumonia” and “di-
arrhea” in the open narrative and “frequent loose/liquid stool
continuing until death”were less commonly reported following
deaths in azithromycin-treated than placebo communities.
The relatively low sensitivity of InterVA for predicting both HIV/
AIDS and diarrhea reported by Murray et al.,14,19 and shown
in Supplemental Table 7, indicates the algorithm may un-
derestimate mortality from these causes. Compared with
SmartVA, InterVAdid predict fewer diarrhea deaths, although
more HIV/AIDS deaths in this study. The relatively higher
sensitivity and lower specificity of InterVA for identifying
pneumonia may lead to an overestimate of pneumonia
mortality. SmartVA, on the other hand, has a particularly low
sensitivity for pneumonia, which would contribute to the
lower proportions of pneumonia reported in this study using
the SmartVA algorithm, especially before redistribution of
unknown causes.
The differences in sensitivity and specificity of the two al-
gorithms reflect the fact that VA is a blunt diagnostic tool, less
suited to individual-level diagnosis compared with population-
level prediction of cause-specific mortality fractions. Nonethe-
less, primary analyses by the two algorithms are not necessarily
contradictory, both suggesting lower pneumonia mortality
in azithromycin communities and InterVA suggesting lower
HIV/AIDS mortality, whereas SmartVA suggests lower di-
arrhea mortality. These diagnoses are particularly difficult
to distinguish retrospectively in the absence of clinical in-
vestigation; diarrhea may often be the immediate cause of
death when the underlying cause is HIV/AIDS. The direct
analysis of VA responses would suggest lower pneumonia and
diarrhea in the azithromycin group; the similar maternal HIV
positivity between groups, estimating HIV exposure, does not
TABLE 2
Deaths in placebo- and azithromycin-treated clusters due to the top 10 causes using InterVA
InterVA output cause Number of deaths in placebo arm (%) Number of deaths in azithromycin arm (%) Number of deaths in both arms (%)
Malaria 256 (42.9) 245 (45.9) 501 (44.3)
HIV/AIDS-related death 103 (17.3) 71 (13.3) 174 (15.4)
Acute respiratory infection, including
pneumonia
94 (15.7) 77 (14.4) 171 (15.1)
Diarrheal diseases 48 (8.0) 45 (8.4) 93 (8.2)
Indeterminate 19 (3.2) 15 (2.8) 34 (3.0)
Acute abdomen 16 (2.7) 15 (2.8) 31 (2.7)
Meningitis and encephalitis 10 (1.7) 16 (3.0) 26 (2.3)
Severe malnutrition 12 (2.0) 9 (1.7) 21 (1.9)
Accidental exposure to smoke fire and flame 7 (1.2) 6 (1.1) 13 (1.2)
Epilepsy 2 (0.3) 9 (1.7) 11 (1.0)
Other 30 (5.0) 26 (4.9) 56 (4.9)
Total 597 (100) 534 (100) 1,131 (100)
TABLE 3












deaths in placebo arm
after redistribution
Percentage of deaths
in azithromycin arm after
redistribution
Percentage of
deaths in both arms
after redistribution
Malaria 198 (33.2) 184 (34.5) 382 (33.8) 39.1 40.9 40.0
Undetermined 133 (22.3) 131 (24.5) 264 (23.3) 0.0 0.0 0.0
AIDS 71 (11.9) 70 (13.1) 141 (12.5) 12.8 13.2 13.0
Diarrhea/dysentery 79 (13.2) 56 (10.5) 135 (11.9) 16.1 13.0 14.6
Other digestive diseases 44 (7.4) 50 (9.4) 94 (8.3) 7.6 9.5 8.5
Pneumonia 35 (5.9) 20 (3.8) 55 (4.9) 10.3 10.0 10.1
Fires 8 (1.3) 6 (1.1) 14 (1.2) 1.5 1.3 1.4
Childhood cardiovascular
diseases
5 (0.8) 4 (0.8) 9 (0.8) 1.1 1.1 1.1
Meningitis 5 (0.8) 3 (0.6) 8 (0.7) 2.0 2.5 2.2
Other infectious diseases 6 (1.0) 1 (0.2) 7 (0.6) 1.8 1.3 1.6
Other 13 (2.2) 9 (1.7) 22 (2.0) 7.7 7.2 7.5
Total 597 (100) 534 (100) 1,131 (100) 100 100 100
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provide evidence for whether or not the diarrhea is likely to be
HIV-related. The PP analyses did not show any greater effect
than the ITT analyses for pneumonia, diarrhea, or HIV/AIDS,
providing no evidence that these were solely individual-level ef-
fects in those treated, as opposed to community-level effects.
An effect of azithromycin on respiratory and gastrointestinal
infections, including on a background of HIV exposure or in-
fection, leading to a reduction in the rate of pneumonia and
diarrhea as immediate causes of death, is certainly plausi-
ble. Azithromycin is an effective treatment for community-
acquired pneumonia, including the major etiological causes,
Streptococcus pneumoniae and Haemophilus influenzae.23
Single-dose azithromycin has been shown to reduce oro-
pharyngeal carriage of S. pneumoniae and decrease in-
cidence of pneumonia.24,25
Azithromycin has efficacy against themain bacterial causes
of fatal childhood diarrhea, namely, enteropathogenic and
enterotoxigenic Escherichia coli, Shigella spp., Campylobac-
ter spp., Salmonella spp., and Vibrio cholerae.26 Furthermore,
azithromycin has anti-inflammatory properties that, combined
with a reduction in gut pathogens, may reduce chronic
immunostimulation caused by environmental enteric dys-
function and consequently improve nutritional status.27,28
Evidence from the MORDOR Niger study site indicates
there may be changes to the gut microbiome following azi-
thromycin MDA, although improvements in anthropometry
measurements, as an assessment of nutritional status, have
not previously been associated with azithromycin MDA.29–31
The REALITY trial identified a 27% reduction in mortality
over 24 weeks in adults and children aged 5 years and
older when commencing antiretroviral therapy (ART) plus an
enhanced antimicrobial prophylactic regimen of trimethoprim–
sulfamethoxazole, isoniazid–pyridoxine, fluconazole, albenda-
zole, and a 5-day course of azithromycin, compared with
commencing ART plus standard prophylaxis of trimethoprim–
sulfamethoxazole only.32 The multiple dimensions to the
enhanced regimen make it difficult to identify the specific
intervention causing the reduction in mortality, but further
analysis by Post et al.33 indicated mortality reductions from
cryptococcosis and unknown causes, and not from severe
bacterial infections, potentially azithromycin-responsive
infections or tuberculosis.
REALITY investigated mortality in adults and older children
during ART commencement, so it is not directly compara-
ble with child mortality in the MORDOR trial; antimicrobial
benefits and prophylactic effects of azithromycin against
chronic disease-causing pathogens such as M. avium com-
plex and Pneumocystis jirovecii could play a role in reducing
HIV/AIDS mortality in low-resource settings where HIV is
underdiagnosed.34 Prevalence of HIV infection in Malawi is
approximately 9.2% in adults aged 15–49 years.35 HIV
transmission is known to be a problem in fishing communities
in Mangochi District because of practices associated with the
market chain.36 AmongHIV-infected children aged0–14 years
nationally, approximately 61%were estimated to be receiving
ART in 2018.35 In the setting of significant levels of
TABLE 4
Cause-specific mortality by intention-to-treat for the four main inferred causes of death in the study area using InterVA
Deaths/person-years Rate per 1,000 person-years (95% CI) Rate ratio* (95% CI) P-value
Pneumonia
Placebo 94/66,935 1.40 (1.15–1.72) 1
Azithromycin 77/66,837 1.15 (0.92–1.44) 0.82 (0.60–1.12) 0.22
Malaria
Placebo 256/66,935 3.82 (3.38–4.32) 1
Azithromycin 245/66,837 3.67 (3.23–4.15) 0.95 (0.78–1.16) 0.64
HIV/AIDS
Placebo 103/66,935 1.54 (1.27–1.87) 1
Azithromycin 71/66,837 1.06 (0.84–1.34) 0.70 (0.50–0.97) 0.03
Diarrhea
Placebo 48/66,935 0.72 (0.54–0.95) 1
Azithromycin 45/66,837 0.67 (0.50–0.90) 0.95 (0.61–1.49) 0.84
* From random-effects Poisson model adjusting for clustering at the level of the randomization unit.
TABLE 5




person-years (95% CI) Rate ratio* (95% CI) P-value





Placebo 35/66,935 0.52 (0.38–0.73) 1 0.92 1
Azithromycin 20/66,837 0.30 (0.19–0.46) 0.58 (0.33–1.00) 0.05 0.80 0.87
Malaria
Placebo 198/66,935 2.96 (2.57–3.40) 1 3.49 1
Azithromycin 184/66,837 2.75 (2.38–3.18) 0.93 (0.76–1.14) 0.49 3.27 0.94
HIV/AIDS
Placebo 71/66,935 1.06 (0.84–1.34) 1 1.14 1
Azithromycin 70/66,837 1.05 (0.83–1.32) 0.99 (0.71–1.38) 0.95 1.05 0.92
Diarrhea
Placebo 79/66,935 1.18 (0.95–1.47) 1 1.44 1
Azithromycin 56/66,837 0.84 (0.64–1.09) 0.71 (0.51–1.00) 0.05 1.04 0.72
* From random-effects Poisson model adjusting for clustering at the level of the randomization unit.
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undiagnosed HIV/AIDS, an antibacterial agent could prevent
or delay serious infections.
In this study, malaria was the most common cause pre-
dicted by both VA analysis algorithms but there was no evi-
dence for an effect of azithromycin MDA on malaria mortality.
Azithromycin is a weak antimalarial agent, and previous
studies have indicated there may be reductions in malaria
morbidity following azithromycin MDA.4–6,37 Recent assess-
ment from the MORDOR trial in Niger indicated reduced
malaria parasitemia in azithromycin-treated communi-
ties.38 However, morbidity assessments as part of the
MORDOR trial in Tanzania indicated no difference in fever
FIGURE 1. Cause-specificmortality ratesby intention-to-treat for the leading causesof childmortality over the four follow-upperiodsof the study.
1324 HART AND OTHERS
or anemia between azithromycin and placebo arms.39 A
study comparing seasonal malaria chemoprevention (SMC)
to SMC plus azithromycin in Burkina Faso and Mali, which
have lower year-round malaria transmission than Malawi,
reported no difference in mortality between groups, although
reductionswere evident inmorbidity due togastrointestinal and
respiratory infections and nonmalarial febrile illness with the
addition of azithromycin.40
A significant limitation of this study is that MORDOR was
powered to detect a difference in overall mortality at three
study sites and consequently the sample size is low for this
study, first because it is limited to one of the three MORDOR
FIGURE 1. Continued.
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sites and second because it is assessing cause-specific mor-
tality rather thanall-causemortality. Thestudy is underpowered
to provide strong conclusions regarding cause-specific mor-
tality rates, and the small effect estimates may represent type II
error. Relatively small effect sizes for the major causes of child
mortality may be clinically important and this study provides
first estimates for how azithromycin may reduce child mor-
tality for hypothesis generation and further investigation.
Verbal autopsy is recognized as the only feasiblemethod for
determining the cause of death in the absence of a clinical
diagnosis in low-resource settings.41 Automated analysis of
VA interviews improves the affordability and reproducibility of
VA compared with physician review; however, the accuracy
of individual-level diagnoses should not be assumed to be as
accurate as medical certification of cause of death.12 Using
the twomain VA questionnaires, there is variation between the
prediction of the main causes of death, so for the purposes of
this investigation of the potential mechanisms of action of
azithromycin, output from both algorithms was presented.
The use of medical records and medical certificates of cause
of death for in-facility deaths was investigated before the
study but not pursued as, paradoxically, deaths that occurred
in or on the way to a health facility were among the hardest to
identify and categorize as there was no requirement for HSAs
to report them,andhealth center dataweregenerally absent or
impossible to link to the community census. Any medical re-
cords retained by the family were reviewed by the VA team,
and there are specific VA questions concerning diagnoses
from the health system that are used in the algorithms for
predicting cause of death.
In addition, VA, despite being used increasingly to estimate
cause of death patterns where more sophisticated methods
are not practicable, is a relatively imprecise instrument that
relies on details of the final illness recalled by family members.
Accuracy of recall for VA has been estimated to decrease by
approximately 0.6% per month following the death, and it is
recommended that, where possible, VA should be completed
within 12 months.21,42 Verbal autopsy completion for this
study tookplace assoonaspossible following identification of
the death from the census, and after the customary 1-month
mourning period, however, many visits were required to trace
family members for some children as households in the study
area move quite frequently, especially after a child’s death.
The median delay of 5 months in this study and with 87% of
VAs completed within 12 months is within the normally ac-
cepted range and is not expected to have significantly af-
fected the accuracy of predicted diagnoses.
Finally, this study used the WHO 2014 VA questionnaire,
which was designed to facilitate the use of both SmartVA and
InterVA for assigning cause of death.43 The 2014 instru-
ment includes all questions required for InterVA, although not
the exact wording for all questions from the PHMRC question-
naire used by SmartVA. A further updated questionnaire, re-
leased in 2016 after this study started, is fully compatible with
both algorithms. Most questions required as input for SmartVA
are similar to those in the 2014 questionnaire, although the
performance of SmartVA may be slightly reduced compared
with having input from theWHO2016questionnaire orPHMRC
questionnaire. The benefits of having analysis from these two
main algorithms for a wider discussion of the implications of
the data were deemed to outweigh the potential for a slight
decrease in performance. There is a more recently developed
statistical tool for producing cause of death data from VA in-
terviews (InSilicoVA), which aimed to improve on the other
methods by sharing uncertainty between cause of death
assigned for specific individuals and the population distribution
of causes of death.44 Adding a third analysis method with as-
sociated increased complexity was not attempted for this study.
Although this study is not able toprovide strongevidenceon
the causes of death in the MORDOR trial, the data have been
presented fully to enable generation of hypotheses regarding
mechanisms of effect of azithromycin on child mortality. The
TABLE 6
Comparison of verbal autopsy open response terms and question endorsements related to the major causes of child mortality between azi-
thromycin- and placebo-treated communities
VA item
Intention-to-treat analysis Per protocol analysis
Total deaths
Number of interviews in
which item endorsed (%) P-value* Total deaths
Number of interviews in
which item endorsed (%) P-value*
Open response term “malaria”
Placebo 597 273 (45.7) 461 220 (47.7)
Azithromycin 534 262 (49.1) 0.26 431 217 (50.3) 0.44
Open response term “pneumonia”
Placebo 597 49 (8.2) 461 40 (8.7)
Azithromycin 534 27 (5.1) 0.03 431 22 (5.1) 0.04
Open response term “diarrhea”
Placebo 597 131 (21.9) 461 96 (20.8)
Azithromycin 534 90 (16.9) 0.03 431 75 (17.4) 0.19
Maternal test positive for HIV
Placebo 597 45 (7.5) 461 35 (7.6)
Azithromycin 534 41 (7.7) 0.93 431 37 (8.6) 0.59
Frequent loose/liquid stool continuing until death
Placebo 597 222 (37.2) 461 170 (36.9)
Azithromycin 534 161 (30.1) 0.01 431 133 (30.9) 0.06
Very severe cough
Placebo 597 56 (9.4) 461 44 (9.5)
Azithromycin 534 48 (9.0) 0.82 431 38 (8.8) 0.70
Severe fever
Placebo 597 282 (47.2) 461 225 (48.8)
Azithromycin 534 261 (48.9) 0.58 431 202 (46.9) 0.56
* From test of proportions.
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data suggest the mortality reduction in the MORDOR trial in
Malawi may have been due to effects on pneumonia and di-
arrhea or HIV/AIDSmortality. Larger studies will be required to
clearly define the effects of azithromycin MDA on cause-
specific child mortality.
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27. Culić O et al., 2002. Azithromycin modulates neutrophil function
and circulating inflammatory mediators in healthy human sub-
jects. Eur J Pharmacol 450: 277–289.
28. Weisz AJ, Manary MJ, Stephenson K, Agapova S, Manary FG,
Thakwalakwa C, Shulman RJ, Manary MJ, Abnormal gut in-
tegrity is associated with reduced linear growth in rural Mala-
wian children. J Pediatr Gastroenterol Nutr 55: 747–750.
29. Burr SE,Hart J, EdwardsT,Harding-EschEM,HollandMJ,Mabey
DCW, Sillah A, Bailey RL, 2014. Anthropometric indices of
Gambianchildrenafter oneor three annual roundsofmassdrug
administration with azithromycin for trachoma control. BMC
Public Health 14: 1176.
30. Doan T et al., 2019. Gut microbiome alteration in MORDOR I: a
community-randomized trial of mass azithromycin distribution.
Nat Med 25: 1370–1376.
31. Keenan JD et al., 2019. Linear growth in preschool children
treated with mass azithromycin distributions for trachoma: a
cluster-randomized trial. PLoS Negl Trop Dis 13: e0007442.
MORDOR-MALAWI CAUSE OF DEATH 1327
32. Hakim J et al.; REALITY Trial Team, 2017. Enhanced prophylaxis
plus antiretroviral therapy for advanced HIV infection in Africa.
N Engl J Med 377: 233–245.
33. Post FA et al., 2018, Causes and timing of mortality andmorbidity
among late presenters starting antiretroviral therapy in the
REALITY trial. Clin Infect Dis 66 (Suppl_2): S132–S139.
34. Dunne MW, Bozzette S, McCutchan JA, Michael PDubé, Sattler
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